Interleukin-13 (IL-13): The "Executor" of Tissue Repair and Pathological Remodeling

Interleukin-13 (IL-13) is a key effector cytokine in type 2 immune responses, sharing significant functional overlap with IL-4 but exhibiting distinct target cell specificity. IL-13's primary role is not to initiate immune responses but to directly act on structural cells in tissues (e.g., epithelial cells, fibroblasts, smooth muscle cells), executing terminal effects such as mucus secretion, tissue fibrosis, and airway hyperresponsiveness. It serves as the core "executor" in the pathogenesis of allergic diseases and tissue repair/fibrosis processes, with its dysregulation directly leading to chronic pathological states characterized by tissue remodeling.

IL-13 is primarily produced by activated type 2 helper T cells (Th2), group 2 innate lymphoid cells (ILC2s), basophils, and mast cells. Its gene is closely linked to the IL-4 gene on the chromosome but exhibits divergence in expression regulation and function. IL-13 is a ~10 kDa four-helix bundle monomeric protein.

The biological effects of IL-13 are mediated through its specific receptor complexes, the complexity of which determines its unique functional positioning:

Type II IL-4 receptor (primary functional receptor): This is the main pathway through which IL-13 exerts its effects. The receptor consists of the IL-4Rα chain (CD124) and the IL-13Rα1 chain. IL-13 first binds to IL-13Rα1, which then recruits the IL-4Rα chain to form a signaling-capable heterodimer. Notably, this receptor is also one of IL-4's signaling pathways (though not its primary one), explaining the molecular basis of their functional overlap.

IL-13Rα2 decoy receptor: This is a high-affinity monomeric receptor that binds IL-13 but lacks intracellular signaling domains. It primarily acts as a "scavenger," negatively regulating IL-13's bioactivity to prevent excessive responses. Its expression or function may be dysregulated in fibrotic diseases.

Non-hematopoietic cell bias: Unlike IL-4, which can act on lymphocytes, IL-13 receptors are more abundantly and critically expressed on non-hematopoietic cells (e.g., epithelial cells, fibroblasts, endothelial cells, smooth muscle cells), making IL-13 a direct "messenger" linking the immune system to tissue structures.

IL-13's core function is to directly instruct tissue cells to undergo structural and functional changes, with its effects primarily manifesting in three aspects:

1. Induction of goblet cell metaplasia and mucus hypersecretion
Direct instruction to epithelial cells: IL-13 can directly act on airway epithelial cells, inducing their differentiation into goblet cells (metaplasia) and significantly upregulating mucin gene (e.g., MUC5AC) expression, leading to excessive mucus production. This is the direct cause of airway mucus plug formation and airflow obstruction in asthma and chronic obstructive pulmonary disease (COPD).

2. Promotion of tissue fibrosis
Activation of fibroblasts: IL-13 is a potent pro-fibrotic factor. It directly stimulates fibroblast proliferation and promotes their synthesis and secretion of extracellular matrix components such as collagen I, III, and fibronectin, leading to tissue scarring and functional loss.
Induction of alternatively activated macrophages: In synergy with IL-4, IL-13 drives macrophage polarization toward the M2 phenotype. M2 macrophages further secrete growth factors like TGF-β, forming a positive feedback loop with IL-13 to amplify fibrosis.

3. Mediation of airway hyperresponsiveness
Action on airway smooth muscle: IL-13 enhances airway smooth muscle cell sensitivity to contractile stimuli (e.g., methacholine), i.e., airway hyperresponsiveness (AHR), which is the core pathophysiological basis of reversible airflow limitation and wheezing symptoms in asthma patients.
Induction of eosinophil chemotaxis: By stimulating epithelial cells to produce eosinophil chemotactic factors (e.g., eotaxin), IL-13 synergistically recruits eosinophils to inflammatory sites, exacerbating tissue damage and inflammation.

IL-13's signal transduction heavily relies on the shared IL-4Rα chain, so its core pathways are highly similar to those of IL-4.

JAK-STAT pathway (core pathway):
STAT6 activation is pivotal: After IL-13 binds to the type II receptor, it activates JAK1 coupled to the IL-4Rα chain and JAK2/Tyk2 coupled to the IL-13Rα1 chain. These kinases phosphorylate the receptor, providing docking sites for STAT6. Phosphorylated STAT6 dimers translocate to the nucleus, initiating transcription programs for genes related to mucus secretion (MUC5AC), fibrosis (collagen), and AHR. STAT6 activation is central to nearly all pathological effects of IL-13.

AP-1 pathway:
Activated by IL-13 in coordination with STAT6, it participates in regulating the expression of some pro-inflammatory and pro-fibrotic genes.

Synergy with the TGF-β pathway:
IL-13-induced M2 macrophages and certain tissue cells secrete active TGF-β, which, through the canonical Smad pathway, strongly synergizes with the STAT6 pathway, serving as a key amplifier of progressive fibrosis.

Due to its direct effects on tissue structure, abnormal IL-13 expression is closely associated with various chronic inflammatory and fibrotic diseases.

Severe asthma (especially type 2 inflammatory phenotype): IL-13 is the most direct effector driving asthma's core pathological features—mucus hypersecretion, AHR, and airway remodeling (fibrosis). Anti-IL-13 monoclonal antibodies (e.g., tralokinumab, lebrikizumab) have shown promising clinical efficacy in asthma subgroups with high eosinophil counts or high periostin (an IL-13-induced biomarker), improving lung function and reducing acute exacerbations.

Atopic dermatitis: IL-13 is highly expressed in skin lesions, directly causing skin barrier dysfunction (inhibiting filaggrin expression), abnormal keratinocyte proliferation, and chronic itching. Dupilumab (anti-IL-4Rα), by simultaneously blocking IL-4 and IL-13 signaling, has become a revolutionary therapy, while specific anti-IL-13 drugs are also undergoing clinical trials in this field.

Chronic rhinosinusitis with nasal polyps: IL-13 drives eosinophilic inflammation, edema, and remodeling in nasal polyp tissue, making it an important therapeutic target.

Idiopathic pulmonary fibrosis: Although traditionally not associated with Th2 responses, studies show IL-13 signaling activation in the lungs of IPF patients, where it may promote myofibroblast activation and M2 polarization to participate in fibrosis. Targeting the IL-13/IL-13Rα2 axis is an exploratory therapeutic strategy.

Systemic sclerosis: IL-13 may contribute to driving skin and visceral fibrosis.

Liver fibrosis/cirrhosis: In schistosomiasis infection or chronic liver injury models, IL-13 is a key pro-fibrotic factor.

Helminth infections: IL-13 plays a critical protective role in expelling intestinal nematodes, with mechanisms including promoting goblet cell hyperplasia and mucus secretion to "flush" parasites, enhancing smooth muscle contraction to accelerate expulsion, and inducing tissue repair to block parasite migration paths.

Dual and complex roles: In the tumor microenvironment, IL-13 primarily induces M2-type tumor-associated macrophages (TAMs) and promotes fibrosis, creating an immunosuppressive and pro-tumor growth environment. However, for certain tumors expressing IL-13Rα2 (e.g., glioblastoma, pancreatic cancer), this receptor can serve as a target for precision strikes using antibody-drug conjugates or CAR-T cells.

Intervention strategies targeting IL-13 are evolving from simple inhibitor development to biomarker-based precision medicine and combination therapies.

Biomarker-guided therapy: Using blood periostin levels, eosinophil counts, or IL-13-related gene signatures to identify patient subgroups most likely to benefit from anti-IL-13 therapy (e.g., asthma, atopic dermatitis) enables personalized treatment.

Targeting the decoy receptor: Modulating IL-13Rα2 function or utilizing it as a drug delivery vehicle is a novel approach for treating fibrotic diseases and certain cancers.

Multi-target blockade: For severe allergic diseases, combining anti-IL-13 drugs with anti-IgE (omalizumab), anti-IL-5/IL-5R (mepolizumab/benralizumab), or anti-TSLP (tezepelumab) aims to comprehensively inhibit type 2 inflammatory circuits at different stages, representing an important future direction.

Combination with anti-fibrotic drugs: In fibrotic diseases, anti-IL-13 therapy may be combined with standard anti-fibrotic drugs like nintedanib or pirfenidone to achieve additive or synergistic effects.

Bispecific antibodies: Developing bispecific antibodies targeting IL-13 and another key target (e.g., IL-4, TSLP, IL-33 receptor) to enhance efficacy.

Small-molecule inhibitors: Developing inhibitors targeting downstream nodes of the IL-13 signaling pathway (e.g., JAK1, STAT6) to provide oral administration options.

Interleukin-13 is a pivotal effector molecule in type 2 immune responses, bridging immune system activation signals to tissue-level pathological changes—mucus, fibrosis, and hyperresponsiveness. Unlike IL-4, which focuses more on "initiating" and "instructing" immune cells, IL-13 acts like an "engineer" or "construction team" on the front lines, directly executing the "blueprint" for tissue remodeling. From driving airway obstruction in asthma to promoting irreversible organ fibrosis, IL-13's effects profoundly influence the progression and prognosis of chronic diseases. With the advent of precision biologics targeting IL-13 and its pathways, we can now effectively intervene in this core pathological link. Moving forward, through more precise patient stratification, more efficient combination strategies, and more innovative drug designs, targeting IL-13 will continue to provide disease-modifying treatment options for patients with chronic inflammatory and fibrotic diseases.